Cellenkos

Developer of T-cell therapeutics to treat autoimmune and inflammatory diseases

placeHouston, Texas, United States calendar_todayFounded 2016 groups14 employees language cellenkosinc.com

Social engagement

Social engagement: 1.6K social following, 7 posts in the last 12 months — below the industry typical range.

Investor mix

1 investor on record; lead investors include BioVeda China Fund.

Investor typeCountShare
Venture capital1100%

Recent activity

5 May 2026
Milestone
regulatory
27 Apr 2026
Milestone
regulatory
13 Jan 2026
Milestone
regulatory
Coming soon